AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2182447 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg daily oral fluconazole
Number of subjects: 248
Study 2182447 — intervention group
Group type: COMPARATOR
Intervention: Oral polyenes (control)
Number of subjects: 248
Study 391753 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline 50 mg daily
Number of subjects: 20
Study 391753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31986899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received additional home visit with health education materials in English and Navajo)
Number of subjects: 25
Study 31986899 — intervention group
Group type: COMPARATOR
Intervention: Control group (received standard care with one home visit discussing mammography pros/cons and barriers)
Number of subjects: 25
Study 31567567 — intervention group
Group type: EXPERIMENTAL
Intervention: T2Candida
Number of subjects: 0
Study 31567567 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum BDG and T2Candida
Number of subjects: 0
Study 31567567 — intervention group
Group type: EXPERIMENTAL
Intervention: BDG-guided empiric antifungal treatment
Number of subjects: 0
Study 31567567 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR
Number of subjects: 0
Study 27439324 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomosynthesis
Number of subjects: 158
Study 27439324 — intervention group
Group type: COMPARATOR
Intervention: DE imaging
Number of subjects: 158
Study 27439324 — intervention group
Group type: COMPARATOR
Intervention: Conventional chest radiography
Number of subjects: 158
Study 26525422 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath emollients plus standard eczema care
Number of subjects: 423
Study 26525422 — intervention group
Group type: COMPARATOR
Intervention: Standard eczema care only
Number of subjects: 423
Study 24229749 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (72 mg/d)
Number of subjects: 255
Study 24229749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 21561398 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine plus rivastigmine patch
Number of subjects: 172
Study 21561398 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine patch monotherapy
Number of subjects: 172
Study 19321287 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM intervention group
Number of subjects: 48
Study 17688463 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone (LAI-ris)
Number of subjects: 49
Study 17688463 — intervention group
Group type: COMPARATOR
Intervention: Oral atypical antipsychotic (AAP)
Number of subjects: 49
Study 15507939 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose parecoxib sodium 40 mg
Number of subjects: 208
Study 15507939 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose parecoxib sodium 20 mg, 4 times daily
Number of subjects: 208
Study 15507939 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose parecoxib sodium 40 mg, twice daily
Number of subjects: 208
Study 15507939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 15507939 — intervention group
Group type: COMPARATOR
Intervention: Morphine 4 mg
Number of subjects: 208
Study 15507939 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 30 mg
Number of subjects: 208
Study 11514692 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 236
Study 11514692 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 236
Study 9596002 — intervention group
Group type: EXPERIMENTAL
Intervention: Major neurologic complications (metabolic encephalopathy, seizures, psychiatric symptoms, cerebral hemorrhage, cerebral abscess, leukemic meningitis, peripheral neuropathies, myopathies)
Number of subjects: 115
Study 9596002 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor neurologic complications (headache, tremor)
Number of subjects: 115
Study 9596002 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic encephalopathy
Number of subjects: 115
Study 9596002 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival at day 90
Number of subjects: 115
Study 9609369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 30
Study 9609369 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 30
Study 9609369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2666759 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (0.3 microgram/kg intravenously over 15 minutes at the conclusion of cardiac bypass)
Number of subjects: 60
Study 2666759 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60
Study 2666759 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate
Number of subjects: 60
Study 791437 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic absorbable polyglactin suture
Number of subjects: 161
Study 791437 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic absorbable polyglycolic acid suture
Number of subjects: 161
Study 791437 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-absorbable polypropylene suture
Number of subjects: 161
Study 791437 — intervention group
Group type: COMPARATOR
Intervention: Surgeons in training
Number of subjects: 161
Study 31721249 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 360
Study 31721249 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 360
Study 31721249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 31721249 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower UNa (≤60 mmol/L)
Number of subjects: 360
Study 31462203 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard initiation of renal replacement therapy
Number of subjects: 2866
Study 31462203 — intervention group
Group type: COMPARATOR
Intervention: Accelerated initiation of renal replacement therapy
Number of subjects: 2866
Study 28035867 — intervention group
Group type: EXPERIMENTAL
Intervention: SC golimumab 50 mg every 4 weeks through week 12, continued for good responders through week 52 (Group 1)
Number of subjects: 433
Study 28035867 — intervention group
Group type: COMPARATOR
Intervention: SC golimumab 50 mg (Group 2-SC)
Number of subjects: 433
Study 28035867 — intervention group
Group type: COMPARATOR
Intervention: IV golimumab 2 mg/kg (Group 2-IV)
Number of subjects: 433
Study 28035867 — intervention group
Group type: COMPARATOR
Intervention: SC golimumab and IV golimumab (Groups 2-SC and 2-IV)
Number of subjects: 433
Study 28035867 — intervention group
Group type: COMPARATOR
Intervention: SC golimumab and IV golimumab
Number of subjects: 433
Study 28035867 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall trial population
Number of subjects: 433
Study 24867603 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD, 6 mg.kg(‐1))
Number of subjects: 12
Study 24867603 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose (MD, 4 mg.kg(‐1))
Number of subjects: 12
Study 24867603 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (LD, 2 mg.kg(‐1))
Number of subjects: 12
Study 24867603 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 23230069 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube with stylet
Number of subjects: 232
Study 23230069 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube without stylet
Number of subjects: 232
Study 21311871 — intervention group
Group type: EXPERIMENTAL
Intervention: Written materials
Number of subjects: 1174
Study 21311871 — intervention group
Group type: EXPERIMENTAL
Intervention: Videocassette and written materials
Number of subjects: 1174
Study 21311871 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1174
Study 19170120 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-then-suppress
Number of subjects: 59
Study 19170120 — intervention group
Group type: COMPARATOR
Intervention: Suppress-then-process
Number of subjects: 59
Study 19170120 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-avoidance coping conflict
Number of subjects: 59
Study 16946696 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy (100-200 mg/day)
Number of subjects: 1127
Study 16946696 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy with ASH as supplemental medication
Number of subjects: 1127
Study 16946696 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy with ASH vs other psychotropic medications
Number of subjects: 1127
Study 16946696 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine adjunctive therapy with ASH
Number of subjects: 1127
Study 15468370 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum levels of TNF‐sR1
Number of subjects: 274
Study 15468370 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum levels of TNF‐sR2
Number of subjects: 274
Study 15468370 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum levels of TNF‐sR1 and TNF‐sR2
Number of subjects: 274
Study 15468370 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum levels of IL‐6
Number of subjects: 274
Study 15468370 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP, IL‐6sR, IL‐2sR
Number of subjects: 274
Study 11308436 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the CONSORT statement (post-1994)
Number of subjects: 211
Study 11308436 — intervention group
Group type: COMPARATOR
Intervention: Reports from journals that did not adopt CONSORT (control group)
Number of subjects: 211
Study 9220226 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesigyna
Number of subjects: 60
Study 9220226 — intervention group
Group type: EXPERIMENTAL
Intervention: TriNovum
Number of subjects: 60
Study 7955822 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-containing analgesic (APAP/ASA/CAF: 500 mg acetaminophen, 500 mg aspirin, 130 mg caffeine)
Number of subjects: 2811
Study 7955822 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-containing analgesic (APAP/CAF: 1000 mg acetaminophen, 130 mg caffeine)
Number of subjects: 2811
Study 7955822 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg acetaminophen
Number of subjects: 2811
Study 7955822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2811
Study 3211484 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/ml mitomycin eye drops
Number of subjects: 44
Study 3211484 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/ml mitomycin eye drops
Number of subjects: 44
Study 3211484 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 44
Study 31673103 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab for HER2 + EBC (12 months treatment, defined as ≥350 days of exposure within 540 days of initiation)
Number of subjects: 14644
Study 31673103 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab for HER2 + EBC
Number of subjects: 14644
Study 31673103 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab for HER2 + EBC (≥12 months treatment)
Number of subjects: 14644
Study 27780692 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet combined with weight-loss cognitive behavioral therapy
Number of subjects: 88
Study 27780692 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet combined with weight-loss cognitive behavioral therapy
Number of subjects: 88
Study 27780692 — intervention group
Group type: COMPARATOR
Intervention: Both groups pooled (high protein and high carbohydrate)
Number of subjects: 88
Study 25394396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-motor dual-task using auditory cues
Number of subjects: 37
Study 25394396 — intervention group
Group type: COMPARATOR
Intervention: Single-task group (treadmill walking only)
Number of subjects: 37
Study 23410541 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina (A)
Number of subjects: 2364
Study 23410541 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina equivalents (E)
Number of subjects: 2364
Study 23410541 — intervention group
Group type: COMPARATOR
Intervention: Neither angina nor angina equivalents (N)
Number of subjects: 2364
Study 21697075 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 IU/d from fortified ultra-high-temperature pasteurized milk from the United States
Number of subjects: 579
Study 21697075 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 IU/d from fortified pasteurized Mongolian milk
Number of subjects: 579
Study 21697075 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 IU/d from supplements
Number of subjects: 579
Study 21697075 — intervention group
Group type: EXPERIMENTAL
Intervention: a one-time seasonal supplement of 13,700 IU
Number of subjects: 579
Study 21697075 — intervention group
Group type: COMPARATOR
Intervention: unfortified pasteurized Mongolian milk
Number of subjects: 579
Study 18827019 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day testosterone (T)
Number of subjects: 206
Study 18827019 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/day dehydroepiandrosterone (DHEA)
Number of subjects: 206
Study 18827019 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day dehydroepiandrosterone (DHEA)
Number of subjects: 206
Study 18827019 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 206
Study 18827019 — intervention group
Group type: EXPERIMENTAL
Intervention: Young individuals (18-31 years)
Number of subjects: 206
Study 18827019 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly women
Number of subjects: 206
Study 16821176 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary in-patient treatment program
Number of subjects: 307
Study 16821176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense activating group treatment (subgroup analysis)
Number of subjects: 307
Study 16821176 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 307
Study 12719069 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical contact lenses (SPH)
Number of subjects: 15
Study 12719069 — intervention group
Group type: COMPARATOR
Intervention: With-the-rule astigmatism (WTR) contact lenses
Number of subjects: 15
Study 12719069 — intervention group
Group type: EXPERIMENTAL
Intervention: Against-the-rule astigmatism (ATR) contact lenses
Number of subjects: 15
Study 10695822 — intervention group
Group type: COMPARATOR
Intervention: 16 oz whole cow's milk (WCM) daily
Number of subjects: 24
Study 10695822 — intervention group
Group type: COMPARATOR
Intervention: Soy formula daily
Number of subjects: 24
Study 10695822 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic oral iron treatment
Number of subjects: 24
Study 10695822 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of IDA
Number of subjects: 24
Study 10695822 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive WCM intake (30 oz/day or more)
Number of subjects: 24
Study 9137133 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin
Number of subjects: 14
Study 9137133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7870929 — intervention group
Group type: COMPARATOR
Intervention: DHEAS/CRT ratio in elderly controls (aged > 60)
Number of subjects: 74
Study 7870929 — intervention group
Group type: COMPARATOR
Intervention: DHEAS/CRT ratio in female AD patients
Number of subjects: 74
Study 7870929 — intervention group
Group type: COMPARATOR
Intervention: CRT plasma levels in female AD patients
Number of subjects: 74
Study 7870929 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT plasma levels between female and male AD patients
Number of subjects: 74
Study 7870929 — intervention group
Group type: COMPARATOR
Intervention: DHEAS/CRT ratios in AD patients
Number of subjects: 74
Study 3002720 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo Sampoon
Number of subjects: 300
Study 3002720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho Vaginal Tablets (OVT)
Number of subjects: 300
Study 3002720 — intervention group
Group type: EXPERIMENTAL
Intervention: Emko Vaginal Tablets (EVT)
Number of subjects: 300
Study 28816373 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mL simethicone/Pronase solution plus 10 mL lidocaine hydrochloride mucilage (SP/LHM)
Number of subjects: 610
Study 28816373 — intervention group
Group type: COMPARATOR
Intervention: 10 mL lidocaine hydrochloride mucilage (LHM)
Number of subjects: 610
Study 27655503 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal decompression with dynamic and profound adjustment of the gastric tube and abdomen movement (Observation group)
Number of subjects: 36
Study 27655503 — intervention group
Group type: COMPARATOR
Intervention: Routine continuous gastrointestinal decompression (Control group)
Number of subjects: 36
Study 23790120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 50
Study 21174129 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (BT) sleep intervention composed of stimulus control, modified sleep restriction (MSR), relaxation therapy (RT), and sleep hygiene counseling
Number of subjects: 113
Study 21174129 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (BT) sleep intervention
Number of subjects: 113
Study 20600604 — intervention group
Group type: EXPERIMENTAL
Intervention: Real putting condition
Number of subjects: 10
Study 20600604 — intervention group
Group type: COMPARATOR
Intervention: Virtual putting condition
Number of subjects: 10
Study 18349431 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects randomized to estimate the probability of treatment success after learning their diagnosis (after group)
Number of subjects: 0
Study 18349431 — intervention group
Group type: COMPARATOR
Intervention: Subjects randomized to estimate the probability of treatment success before learning their diagnosis (before group)
Number of subjects: 0
Study 15849646 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWT without local anesthesia (Group A)
Number of subjects: 60
Study 15849646 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWT with local anesthesia (Group B)
Number of subjects: 60
Study 15849646 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWT with local anesthesia (Group C)
Number of subjects: 60
Study 12823159 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine at bedtime
Number of subjects: 19
Study 12823159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10571438 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-TV (4 x 10(4) pfu/dose)
Number of subjects: 0
Study 10571438 — intervention group
Group type: COMPARATOR
Intervention: RRV-TV (4 x 10(5) pfu/dose)
Number of subjects: 0
Study 8766483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal pulse oximetry (PO)
Number of subjects: 63
Study 8766483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fetal pulse oximetry)
Number of subjects: 63
Study 1927942 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (30 U/5 min)
Number of subjects: 370
Study 1927942 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (1.5 million IU/1 hour)
Number of subjects: 370
Study 1927942 — intervention group
Group type: EXPERIMENTAL
Intervention: Early patency (both treatments)
Number of subjects: 370
Study 6129609 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined salbutamol-dexamethasone treatment
Number of subjects: 32
Study 6129609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 6129609 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol alone
Number of subjects: 32
Study 6129609 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 32
Study 31327317 — intervention group
Group type: COMPARATOR
Intervention: No-ICAS group (control)
Number of subjects: 709
Study 31327317 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe-ICAS
Number of subjects: 709
Study 31327317 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-ICAS
Number of subjects: 709
Study 27587605 — intervention group
Group type: EXPERIMENTAL
Intervention: MCO AA
Number of subjects: 39
Study 27587605 — intervention group
Group type: EXPERIMENTAL
Intervention: MCO BB
Number of subjects: 39
Study 27587605 — intervention group
Group type: EXPERIMENTAL
Intervention: MCO CC
Number of subjects: 39
Study 27587605 — intervention group
Group type: COMPARATOR
Intervention: High-flux HD
Number of subjects: 39
Study 27587605 — intervention group
Group type: COMPARATOR
Intervention: HDF
Number of subjects: 39
Study 26273724 — intervention group
Group type: EXPERIMENTAL
Intervention: Autobiographical retrieval
Number of subjects: 0
Study 26273724 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 25145581 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushing with intrinsic stripping (Group 2, n = 27)
Number of subjects: 42
Study 25145581 — intervention group
Group type: COMPARATOR
Intervention: Crushing (Group 1, n = 28)
Number of subjects: 42
Study 22958869 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstaining from smoking for 24h
Number of subjects: 275
Study 22958869 — intervention group
Group type: COMPARATOR
Intervention: Smoking as usual
Number of subjects: 275
Study 18270526 — intervention group
Group type: EXPERIMENTAL
Intervention: Food items enriched with mineral nutrients and 1.25, 2.5, and 5.0 g per day of plant sterols during the first, second, and third 5-week periods, respectively
Number of subjects: 71
Study 18270526 — intervention group
Group type: EXPERIMENTAL
Intervention: Food items enriched with mineral nutrients and plant sterols
Number of subjects: 71
Study 18270526 — intervention group
Group type: COMPARATOR
Intervention: Placebo group receiving similar food items without plant sterols
Number of subjects: 71
Study 17441345 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 40
Study 17441345 — intervention group
Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 40
Study 15974216 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Dental Gum (CDG)
Number of subjects: 0
Study 15974216 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Dental Gum (CDG) plus Colgate Winterfresh Gel (CWG)
Number of subjects: 0
Study 15974216 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 0
Study 15974216 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrices
Number of subjects: 0